| 2.42 0.29 (13.62%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.08 |
1-year : | 3.6 |
| Resists | First : | 2.64 |
Second : | 3.08 |
| Pivot price | 1.93 |
|||
| Supports | First : | 1.83 |
Second : | 1.33 |
| MAs | MA(5) : | 2.21 |
MA(20) : | 1.84 |
| MA(100) : | 1.53 |
MA(250) : | 1.84  |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 78.6 |
D(3) : | 81.7 |
| RSI | RSI(14): 73.7 |
|||
| 52-week | High : | 3.3 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ERAS ] has closed above the upper band by 2.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 122.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.65 - 2.66 | 2.66 - 2.67 |
| Low: | 2.11 - 2.12 | 2.12 - 2.13 |
| Close: | 2.4 - 2.42 | 2.42 - 2.44 |
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Fri, 03 Oct 2025
Erasca: Hype Building Into The End Of The Year (Rating Downgrade) (NASDAQ:ERAS) - Seeking Alpha
Thu, 18 Sep 2025
Erasca, Inc. (ERAS) Stock Analysis: Exploring a Potential 173% Upside in the Biotech Sector - DirectorsTalk Interviews
Tue, 02 Sep 2025
Precision Oncology Company Erasca to Share RAS/MAPK Cancer Therapy Updates at Morgan Stanley Conference - Stock Titan
Mon, 18 Aug 2025
Morgan Stanley downgrades Erasca stock to Equalweight on delayed clinical data - Investing.com
Thu, 14 Aug 2025
Promising Penny Stocks To Consider In August 2025 - simplywall.st
Fri, 30 May 2025
Discover May 2025's Top Penny Stocks - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 284 (M) |
| Shares Float | 167 (M) |
| Held by Insiders | 11.6 (%) |
| Held by Institutions | 81.9 (%) |
| Shares Short | 18,620 (K) |
| Shares Short P.Month | 18,810 (K) |
| EPS | -0.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.3 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18 % |
| Return on Equity (ttm) | -31.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -99 (M) |
| Levered Free Cash Flow | -61 (M) |
| PE Ratio | -6.21 |
| PEG Ratio | 0 |
| Price to Book value | 1.84 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|